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ABSTRACT 
Morphine is considered to be metabolized in three distinct metabolic pathways; 
glucuronidation, sulfation and N-demetylation. However, identification of 
morphine-3-sulfate (M3S) and morphine-6-sulfate (M6S) as morphine 
metabolites has not been convincing according to previous literature due to lack 
of reliable reference material and identification based on thin layer 
chromatography. In this thesis reference material for M3S and M6S was 
developed, and a sensitive analytical method for quantification of M3S and M6S 
in urine and plasma with mass spectrometry was also developed. Urine and 
plasma were analysed from different study groups; newborns, heroin addicts and 
terminal cancer patients.  M3S was present in both urine and plasma from all 
study groups. The plasma ratio M3S/morphine-3-glucuronide was found to be 30 
times higher in newborns than in adults. There was weak evidence that M6S 
actually forms in-vivo since only two samples contained detectable 
concentrations of M6S. It was demonstrated that both M3S and M6S was formed 
in-vitro by human liver homogenate but in small amounts. Nevertheless, we have 
demonstrated that both M3S and M6S are morphine metabolites in humans.  
Heroin is a highly addictive morphine derivative that is present on the illicit drug 
market. One of the primary interests in clinical and forensic drug testing is 
determination/identification of heroin intake.  In this thesis a new validated 
routine LC-MS/MS method for urine drug testing of opiates has been evaluated 
leading to increased selectivity and separation power compared to earlier GC-
MS methods. The evaluation displayed that the 6-AM biomarker is a good and 
dependable criterion for a heroin intake. In addition, we have also demonstrated 
that this method can be reduced regarding number of analytes.  
In 11.5 % of 6-AM positive urine samples (n=693) an atypical metabolic pattern 
of morphine and 6-AM was observed after a heroin intake. The atypical pattern 
seemed not to be related to a genetic polymorphism in the enzymes involved 
since  the  same  individual  can  produce  both  “normal”  and atypical pattern. In-
vitro study using liver homogenates revealed that a strong inhibition of 6-AM 
formation was seen for a rearrangement product of thebaine (compound 3). 
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Indeed, this compound could also be identified in all patient samples showing 
the atypical pattern.   
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1   BACKGROUND 
1.1    OPIUM AND MORPHINE 
Opium has been used throughout history as a medicinal plant. It is the condensed 
juice of unripe fruit capsules of the opium poppy, Papaver somniferum. The 
plant grows up to 1-1.5 meters in height with white, violet or purple flowers (1). 
It has been difficult to define where the plant originated but information points to 
the Mediterranean region of Asia Minor. Opium was mainly used for medical 
purposes due to its analgesic and sedative effects, but also as a recreational drug. 
Opium addiction was first described already in the year 1000 by Biruni, an 
Iranian physician. As the use and demand of opium increased the opium poppy 
began to be grown and processed in many countries (2).  
Opium poppy contains a large number of alkaloids (1). Four of them have found 
medicinal use and are isolated from opium as natural products. Morphine is the 
main alkaloid (10-20 %) and the others are codeine (0.8-2.5 %), noscapine (4-8 
%), and papaverine (~1 %). Morphine is relatively easy separated from the other 
alkaloids due to its phenolic properties (1). Morphine was first isolated 1817 
from opium by the German apothecary Friedrich Sertürner who named it 
“morphium”.  A  structure  was  first  proposed  100  years  later.  In the end of the 
19th century  “morphium”  was  readily available and used for treatment of pain 
(3). 
1.2    HEROIN 
Heroin (3,6-diacetylmorphine, diamorphine) was introduced as a cough 
medicine 1898 by a German pharmaceutical company (Farbenfabriken vorm. 
Friedrich Bayer & Co., now Bayer AG) and was sold over the counter. Heroin is 
a highly addictive drug (4). And due to an epidemic misuse of heroin it was 
banned for medical use in the US in 1924. However, in the UK, heroin is still 
used as an analgesic drug (5).  
Illicit heroin is produced from raw opium by acetylation with acetic acid 
anhydride and heat, leading to a chemically impure product. Impurities are 
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remains of opium alkaloids such as morphine, codeine, papaverine and 
noscapine, but illicit heroin also contain impurities as a result of the production 
process (6). Additional acetylated derivatives that are found in heroin are the O-
acetylated acetylcodeine, 6-acetylmorphine and the N-acetylated 
acetylcodamine, acetylnarcotine and the rearrangements products compound 3 
and 4 from thebaine (7, 8).   
Heroin is also extensively mixed with adulterants and/or diluents in order to 
increase the amount of product (9). Some adulterants such as caffeine and 
procaine have a similar bitter taste as heroin (10). Seizures made in Denmark 
have shown continually shifting patterns of adulterants and diluents. In a study, 
the relative amount of 3,6-diacetylmorphine in different street heroin product 
seizures (n=146, during years 2002-2003) were between 3-51% with a mean 
content of 23%. Caffeine and paracetamol were the two most common. Other 
known adulterants are procaine, paracetamol, lead, strychnine (11) griseofulvin, 
diazepam, phenobarbital, piracetam, methaqualone, barbital, ascorbic acid, 
salicylic acid, mannitol, sucrose, glucose, lactos/maltose. (9).  
Heroin is more lipophilic than morphine increasing its ability to pass the blood 
brain barrier. However, heroin is considered as a prodrug and that the 
pharmacological effect is accomplished by its metabolites, 6-acetylmorphine (6-
AM) and morphine. The 3-acetyl moiety in heroin obstructs the binding to the 
stereospecific receptors resulting so that heroin displays low affinity to the 
opioid receptors. Conjugation at the 6-hydroxyl position does not prevent 
binding to the opioid receptor and hence such derivatives have pharmacological 
activity (12).   
In humans, heroin is metabolized by liver carboxyesterases and serum 
pseudocholine esterases into 6-AM and further to morphine (Figure 1) (12). The 
conversion of heroin to 6-AM can also occur non-enzymatically (13, 14) Heroin 
has a short half-life in blood and is estimated to 5-7 min (15).  
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The intermediate 6-AM is formed almost instantly after a heroin intake and has a 
half-life around 20 min in plasma (16, 12).This leads to short window of 
detection (1-2 hours) of 6-AM in plasma. In urine, 6-AM remains longer leading 
to a slightly longer detection window of 2-8 hours (15).  
Heroin is the drug most often implicated in drug overdoses with lethal outcome 
in Europe (17). It is estimated that there are 12-20 million heroin abusers (age 
15-64 years) around the world (18). The risk of death is 20-30 times higher for a 
heroin addict as compared with a non-drug user (19). There are about 100 heroin 
related deaths in Sweden per year (20).  
Heroin creates a state of euphoria, warmth and well-being, constriction of the 
pupils, nausea and respiratory depression. The respiratory depression is usually 
the direct cause of death after a heroin overdose. The continuous use of heroin is 
characterized by persistent cravings, development of tolerance, and dangerous 
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and painful withdrawal symptoms. The risk of drug/heroin overdoses are related 
to a number of factors such as poly drug, alcohol and benzodiazepine use. The 
purity of ingested heroin has also been discussed as a factor. Some investigations 
have concluded that the heroin purity has nothing to do with the heroin deaths 
while some publications have implied that the heroin deaths have been reduced 
when the street heroin purity has decreased (21). Another factor is a period of 
abstinence from heroin and factors related to individual health status (22).  
1.3    HUMAN CARBOXYLESTERASE 
The carboxylesterase (CES) enzymes are a family of phase I enzymes. There are 
three major human CES:s CES1, human CES2 (also known as the human 
intestine CES, hiCES) and human CES3. But also CES4 and CES7 occur in 
humans. Three major CES:s display wide variety of xenobiotics as substrates; 
acetyl salicylic acid, heroin, cocaine, metylphenidate and oseltamivir as well as 
endogenous esters and amides (23). CES1 is highly expressed in the liver but it 
has also in other tissues such as lung epithelia and heart. CES2 is present in the 
small intestine, such as kidney, liver, heart, brain. CES3 has been expressed in 
the liver and gastrointestinal tract in low amount compared to CES1 and CES2. 
No CES:s activity has been detected in blood of humans (24).  
The conversion of heroin to 6-AM is considered only to be catalyzed by both 
CES1 and CES2 in the liver and by pseudocholinesterase in serum, as well as 
non-enzymatically. The formation of morphine from 6-AM is only catalyzed by 
CES2 (13, 14, 25), and CES2 is 1000 times more active than CES1 (25, 26).  
1.4    MORPHINE METABOLISM 
Morphine is naturally occurring in the (-) isomeric form (3). Morphine is 
considered to be metabolized in three distinct metabolic pathways regardless of 
route of administration: glucuronidation (60-70 %), sulfation (5-10 %) and N-
demethylation (1-6 %) (3) (Figure 2). According to the review of Milne 
morphine-3-sulfate (M3S) constitutes 5 % of metabolites after a given dose of 
morphine (3). However, when carefully examining the literature the 
identification of M3S as a morphine metabolite is not convincing according to 
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present day standard due to lack of reference material and identification based on 
thin layer chromatography (TLC). In the early work of Yeh 1975  they did not 
conclude the presence of M3S, but in the later study from 1977 its presence is 
reported and the amount estimated to be about 1 % relative to M3G (27, 28)  
 
 
 
In a clinical study in preterm and newborn children M3S has been identified 
after an iv-dose of morphine by LC with UV detection. The M6S metabolite was 
not detected (29). Sulfation is an important metabolic pathway in fetal life, 
whereas glucuronidation becomes more important in adults (30). Hepatic 
glucuronidation in neonates has been described as immature at birth compared to 
the more mature neonatal hepatic sulfation. Some studies have demonstrated that 
neonates can significantly metabolize xenobiotics however, clearance is 
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considerable less compared to older infants and adults (31). The results obtained 
by Choonara suggested that morphine sulfation activity decreases with age (29). 
Glucuronidation is an important clearance mechanism for many drugs and it is 
catalyzed by the enzymes UDP- glucuronosyl transferases (UGT) (32). The two 
hydroxyl groups of morphine differ in chemical nature. The hydroxyl at the 3-
position is a phenol while the other hydroxyl group at the 6-position is a 
secondary allylic alcohol. The formation of M3G and M6G are both catalyzed by 
the UGT2B7 enzyme. The subenzyme UGT1A also contributes to the formation 
of M3G, but to a lesser extent. M3G does not bind to the opioid receptors and is 
not pharmacologically active (32). M6G has a high affinity to the opioid 
receptors leading to a greater analgesic effect than morphine itself (29). M6G has 
been suggested as a possible an alternative drug to morphine (3).  
The N-demethylation of morphine to normorphine is catalyzed by cytocrom 
P450 (CYP) enzymes, mainly by CYP3A4 (~60 %) and CYP2C8 (~30 %) (33).  
1.4.1 Sulfotransferases 
Hepatic sulfation is a common phase II metabolic mechanism for increasing 
water solubility and decreasing biological activity. Sulfation is considered as a 
detoxification pathway. The sulfation reaction is catalyzed by sulfotransferases 
(SULTs) transferring the sulfonate (SO3-) ion to a hydroxyl or amino function in 
the molecule (34, 35). The sulfonate transfer can be to different acceptor 
molecules. If the sulfonate group is transferred to an oxygen atom the reaction is 
called sulfation otherwise it is called sulfonation (36).  
The membrane bound SULT enzymes catalyzes sulfation of peptides, proteins, 
lipids and carbohydrates. The cytosolic SULT enzymes catalyze the sulfation of 
xenobiotics and small endogenous compounds such as bile acids, steroids and 
neurotransmitters (35). SULT transfers a sulfonate  group  from  3’-
phosphoadenosine-5’  phosphosulfate  (PAPS) (34). Sulfation is a phase II 
reaction, which often works in parallel with glucuronidation on the same 
substrates. It is not known which of these isoenzymes that is important for the 
morphine sulfation (34).  
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1.5 URINE DRUG TESTING 
Detection of drugs in urine is a common laboratory investigation that has 
important clinical and forensic applications. The requirement is analytical 
methods that enable reliable and accurate identification and quantification of the 
parent drug and their metabolites in urine. The common strategy for urine drug 
testing is to perform two analytical investigations for a positive urine sample. 
The first investigation is made with an immunochemical screening method, 
which is fast, simple and relatively inexpensive, but less specific method. The 
second investigation is made on presumptive positives and is a confirmation 
method that is more selective, sensitive and more expensive. The methods for 
confirmation are often using mass spectrometry (37, 38). The combination of 
immunoassay as a screening and mass spectrometry as confirmation methods 
provides analytical results meeting forensic standards (38). In clinical toxicology 
for investigation of acute intoxication and in doping control mass spectrometry is 
often needed also in the screening analysis (39). High specificity and sensitivity 
is a requirement in clinical and forensic toxicology, and doping control due to 
the analytes are often not known and other endogenous compounds or 
xenobiotics may interfere the analysis (40). 
The purpose of opiate drug testing is to determine if there is a drug intake. Since 
morphine is the target analyte in the screening one of the major tasks is therefore 
to determine which type opiate intake that has occurred. Heroin, morphine, 
codeine, ethylmorphine, opium and poppy seed intake can lead to presence of 
morphine in urine, see Table 1. It is therefore of importance to be able to 
differentiate the different possibilities by analyzing different biomarkers and 
their relative ratios (15). One way to determine a heroin intake has been using 
the morphine codeine ratio and another is to use 6-AM as a heroin biomarker. In 
some cases an atypical metabolic pattern of 6-AM relative to morphine has been 
observed (Figure 3) (41-45). 
 
 
  8 
Table 1 Possible sources that can lead to morphine and other related analytes in urine are 
presented.  
 
Intake Analytes 
Heroin 6-AM, morphine, M3G, M6G, codeine and CG 
Codeine Codeine, CG, morphine, M3G and M6G 
Poppy seed Morphine, M3G, M6G, codeine and CG 
Morphine Morphine, M3G and M6G 
 
 
 
 
Figure 1 Simplified presentation of heroin metabolism showing the  
normal and atypical metabolic pattern. The first step from heroin to  
6-acetylmorphine (6-AM) can be catalyzed by both CES1 and CES2 
and by other esterases. The second conversion of 6-AM to morphine  
is mainly catalyzed by CES2.In the subjects showing an atypical  
pattern of heroin metabolism an unknown factor is inhibiting the  
second, enzymatic conversion from 6-AM to morphine. 
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During the last decade a development of less time-consuming and more selective 
analytical methods based on mass spectrometry has taken place (46). The golden 
standard is liquid or gas chromatography hyphenated to mass spectrometry for 
toxicology analyses. The demand for sensitivity and specificity are high due to 
the complex biological matrices which are attained with mass spectrometry (47).  
Drug testing has traditionally been performed using urine samples. However, 
other biological matrices as oral fluid, breath, hair and blood can also be used. 
Different matrices have different detection times and should be chosen 
depending on the clinical requirement (47, 48).  
1.5.1 Immunoassay 
The most commonly used drug screening technique is immunoassay that first 
came in commercial use for drug testing in the 1970:s (38, 49). Different 
commercial tests are EIA (Enzymatic Immunoassay), EMIT (Enzyme Mediated 
Immunoassay Techniques), ELISA (Enzyme Linked Immunosorbent Assay), 
KIMS (Kinetic Interaction of Microparticles in Solution) and CEDIA (Cloned 
Enzyme Donor Immunoassay). They use the same basic principle; competition 
for binding to a selected drug binding antibody. If the analyte is present in the 
sample it will bind to the antibody (49). The binding of the antibody/analyte 
complex will lead to free tracer which is proportional to the drug concentration 
in the sample. The antibody binding site is not specific for a chemical substance 
but will show cross-reactivity to compounds with similar structure.  
In the CEDIA assay for opiates the target analyte is morphine but the cross-
reactivity for 6-AM and M3G is 81 % and for M6G 47 %. Cross-reactivity with 
non-opiate drugs is also occurring leading to false positive results. The CEDIA 
opiate screening gives 13 % false positives (48). The limited specificity makes 
immunoassays only suitable for qualitative screening and a more reliable and 
selective confirmation method is required for attaining accurate final results (38, 
49). 
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1.5.2 GC-MS 
In the 1980:s GC-MS became the method of choice in analytical toxicology 
which provided the requirement of the selectivity and sensitivity to detect and 
quantify the total morphine and total codeine concentrations. The sample 
preparation often consists of hydrolysis, extraction and derivatization (37, 50). 
Gas chromatography separates the urine samples components based on the 
components volatility and polarity. The separation of compounds occurs due to 
different retention times between the analytes. To acquire an accurate 
identification three characteristic ions are monitored (51). When hydrolysed 
conjugated morphine metabolites (3- and 6-morphineglucuronide and 3- and 6-
morphine sulfate) as well as 6-AM will convert to morphine which result in the 
measurement of total morphine and codeine concentrations (37).  
The GC-MS methods are safe and reliable but have some disadvantages such as 
need for time consuming sample preparation and relatively long run times. The 
confirmation with GC-MS also leads to lack of important information regarding 
the individual morphine metabolites.  
1.5.3 From HPLC to LC-MS/MS 
In high performance liquid chromatography (HPLC) analytes are being separated 
between a solid stationery phase and a mobile phase consisting of buffer and 
organic solvents. Often reversed phase chromatography is used which is when 
the stationary phase is lipophilic and the mobile phase is more hydrophilic (52).   
The combination of liquid chromatography with mass spectrometry (LC-MS) 
has provided a technique with unique sensitivity and selectivity. The 
combination of these two technologies was based on the development of the 
electrospray interface. The difficulty in combining LC with MS is due to the 
liquid mobile phase that needs to vaporize in the ion source and enter the high 
vacuum MS system. The breakthrough arose when the interface of electrospray 
ionization (ESI) and atmospheric pressure chemical ionisation (APCI) was 
introduced (37, 53). In 2002 professor John Fenn, who invented the electrospray 
interface,  was  awarded  the  noble  prize  in  chemistry  for  “development  of  
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methods  for  identification  and  structure  analyses  of  biological  macromolecules” 
(54).  
The ion source (Figure 4) is the interface between LC and the mass spectrometer. 
The mobile phase flow from the LC is sprayed into the ion source via a capillary 
needle. High temperature and drying gas is applied in the ion source which will 
make the mobile phase evaporate and ions in gas phase are formed. An electrical 
gradient is formed between the capillary needle and the entrance to the mass 
analyser which will make the ions enter the mass spectrometer (55). The 
transformation of ions from liquid to gas phase as well as the migrations of the 
ions from atmospheric pressure to high vacuum, are critical steps.  
One drawback of LC-MS is the occurrence of matrix effects. Matrix effects arise 
when the analytes of interest co-elutes with matrix components. Less volatile 
compounds change the droplets formation or droplets evaporation. This 
phenomenon will affect the amount of charged ions in the gas phase reaching the 
detector (56). This will lead to suppression or an enhancement of the detector 
response. Ion suppression has been demonstrated to be more prominent using 
ESI compared to APCI. Though, the choice of sample preparation will also 
influence the matrix effect (37, 53). There are two common approaches for 
studying matrix effects. The first is a post-column infusion of the analytes of 
interest while injecting a blank matrix sample. This will lead to a constant signal. 
in the detector if there are no any eluting compounds that will suppress or 
enhance the ionization (57). The second approach is determination and 
comparison of peak areas in different sample sets. Analytes spiked in neat 
solution, analytes spiked before extraction in blank matrix and analytes spiked 
after extraction in blank matrix (58). These experiments will then be used for 
calculation of the matrix effect as well as the recovery and process efficiency 
(59).  
The identification of an unknown analyte is secured based on accurate retention 
time and mass spectral data. One advantage with mass spectrometry for 
quantitative bioanalysis is the possibility to use isotope labelled analogues as 
internal standards. Deuterated analogs have the identical chemical properties as 
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the analytes and will compensate for possible losses during sample preparations 
and/or changes in detector response. This leads to increased accuracy and 
precision (60).  
The mass spectrometer consists of a quadropole mass filter (Figure 4), which is 
composed of four parallel rods having alternating voltage applied. The charged 
ions from the ion source are focused and transferred between the rods into the 
detector. The ions will be influenced by the electrical field and only ions with the 
correct m/z ratio will pass through and enter the detector. Ions with wrong m/z 
ratios will hit one of the rods due to incorrect amplitude (61).  
The tandem mass spectrometry (MS/MS) consists of three quadropoles linked 
together. The second quadropole (Q2) will function as a collision cell. A 
precursor ion, often the molecular ion, is selected in Q1 and then fragmented in 
Q2 by applying high energy and collisions with N2 or Ar. A fragment is than 
selected in Q3, called product or daughter ion, and is entering the detector. This 
type of monitoring is called selected reaction monitoring (SRM) (62).  
 
Figure 4 A LC connected to a tandem mass spectrometer, which consist of 3 qudropoles. Q1 and 
Q3 function as mass filters and Q2 function as a collision cell.  
The more modern ultra-high performance liquid chromatography (UHPLC) is 
widely used since a few years ago. The pumps are designed to operate at higher 
pressures than conventional HPLC leading to the capability to function with 
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stationary phases of small sub-2µm particles. These systems results in increased 
separation power and reduced retention times (47).  
The independent confirmation method is an important part of the drug testing 
strategy, confirming the screening result. SIM or SRM are generally used. To 
secure the selectivity two SRM transitions are monitored. The identification 
criteria are correct chromatographic retention time and correct relative ratio 
between the monitored ions (56).  
In the beginning of the 1980:s a HPLC with ultra violet (UV) detection was 
developed for determination of morphine and metabolites in urine and plasma (3, 
63). This method was important for the study of morphine pharmacokinetics (3) 
This method was the first to determine morphine, M3G and M6G in urine and 
plasma and was based on sample preparation using solid phase extraction (63).  
LC was hyphenated with MS in the 1990:s (56). In the middle of the 1990:s the 
beginning of using LC-MS for opiate analysis in plasma and to some extent 
urine was introduced (46, 64, 65). Both ESI and APCI interface has been used 
for opiate analysis (37, 53, 66, 67). 
The introduction of LC-MS/MS analysis increases the selectivity and sensitivity 
further. Improved selectivity will allow less sample purification. This will not 
necessarily promote an increase of the matrix effect ion suppression (37). The 
use of LC-MS/MS got more common for determination of morphine and its 
metabolites in plasma. The sample preparation of choice was still solid phase 
extractions although there were some studies regarding protein precipitations 
(53, 68-70). A few years later direct injection or dilute and shoot was developed 
for opiate analysis in urine (53, 65). 
To demonstrate that bioanalytical methods are reliable and reproducible for the 
intended use a validation is needed. Guidelines from European Medicines 
Agency (EMA) (71)  and the U.S Food and Drug Administration (FDA) (72) 
have been proposed for method validation concerning; selectivity, sensitivity, 
reproducibility, carry-over, calibration, accuracy and precision, dilution integrity, 
matrix effect and stability (59).  
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2  AIMS 
The overall aim of this thesis was to gain additional knowledge regarding 
morphine and heroin metabolism by focusing on 6-acetylmorphine, morphine-3-
sulfate and morphine-6-sulfates. Both bioanalytical and clinical aspects were of 
interest.  
 
The specific aims were: 
Study I    
x Prepare reference material for morphine-3-sulfate and morphine-6-sulfate 
since they were not commercially or otherwise available.  
x Develop an LC-MS/MS method for urine and plasma.  
x Application in a preliminary study to confirm the metabolites in plasma 
and urine.  
Study II  
x Validate a routine LC-MS/MS urine drug testing method for opiates 
regarding reliability and biomarkers.  
x To study if the number of analytes could be reduced and to evaluate how 
this would effect the interpretation of possible intake. 
Study III  
x Thoroughly investigate morphine-3-sulfate and morphine-6-sulfate and 
their presence and formation in-vivo and in-vitro.  
Study IV  
x Study the metabolic interaction of heroin metabolism.  
x Study why morphine is not formed after a heroin 
administration/ingestion in some individuals.  
x Investigate and confirm this inhibition both in-vivo and in-vitro. 
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3 METHODS 
3.1 CLINICAL SAMPLES 
3.1.1 Study I 
De-coded surplus urine and plasma samples from the routine flow sent to the 
laboratory for analysis were used. The urine samples were selected based on the 
presence of the heroin metabolite 6-AM (>2 ng/ml). Ethical permit Dnr 
2008/1087-32.  
3.1.2 Study II 
Urine samples studied were sent to laboratory for drug testing. All confirmed 
opiate positive urine samples during a four year time period are included 
(n=3155).  In addition, 199 de-coded surplus urine samples from the routine flow 
were analyzed for method comparison with GC-MS. Ethical permit Dnr 
2008/1087-32.  
3.1.3 Study III 
Samples were collected from 11 cancer patients treated with morphine 
(Dolcontin) per os or via continuous, subcutaneous infusion. From each patient 
one blood and urine sample was collected at the same time-point. Samples were 
collected twice from the same patient when possible which resulted in 13 plasma 
and 12 urine samples collected. Ethical permits Dnr 2010/570-32; 2012/1839-
31/4.   
In addition, 62 blood samples were analyzed from 21 newborns treated with 
morphine by continuous infusion as part of the European FP7 NeoOpioid 
project. A maximum of four samples with a total blood volume less than 0.8 ml 
were collected from an existing catheter from each patient. Ethical permit Dnr 
2010/570-32.   
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Further 196 de-coded surplus urine samples from heroin drug addicts were 
analyzed. The samples were selected based on a confirmed positive result for 6-
AM (>2 ng/ml). Ethical permit Dnr 2008/1087-32.  
 
3.1.4 Study IV 
De-coded surplus urine samples from the routine flow sent to the laboratory for 
opiate analysis. The first selection was based on a positive screening result (cut 
off >300 ng/ml) and the second selection was based on positive confirmation 
result (6-AM >2 ng/ml). A total number of 693 urine samples were evaluated.  
Ethical permit Dnr 2008/1087-32.  
3.2 LIVER TISSUE AND CYTOSOL  
3.2.1 Study III and IV 
In-vitro studies were performed on human livers and one pool of fetal cytosol 
Ethical permits Dnr 429/01; 280/00. 
3.3 SAMPLE PREPARATION PROCEDURES  
3.3.1 Plasma; Study I and III 
The sample preparation of plasma consisted of a protein precipitation with 
acetonitrile. Fifty microliter plasma with 100 µl acetonitrile containing 
deuturated internal standards (M-d3, M3G-d3 and M6G-d3) was vortex mixed for 
~10 seconds. The mixture was centrifuged for 10 min at 3000 rpm. The 
supernatant was evaporated with N2 at 40 ºC until dryness and further 
reconstituted with 30 µl aqueous 0.1 % formic acid.  
3.3.2 Urine; Study I-IV 
The urine samples were diluted five-fold with water. An aliquot of 125 µl water 
containing deuturated internal standard was added to 25 µl urine in an 
autosampler vial.    
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3.3.3 Liver cytosol; Study III 
Human liver cytosol pools was incubated with 100 µM morphine in TRIS HCl 
buffer (0.05 M with 0.25 mM MgCl2) pH 7.4 and 0.05 M PAPS. The incubation 
time were 25 min at 37 ºC the total volume were 125 µl. The reaction was 
stopped by adding 125 µl ice-cold acetonitrile. The supernatant was removed 
and stored at -20 ºC prior analysis after centrifugation at 4000 × g for 15 min at 4 
ºC.  
3.3.4 Liver homogenate; Study IV 
Pieces of human liver tissues were homogenized in 0.05 M TRIS-HCl buffer, pH 
~7.5. A volume of 10 µl liver homogenate, 0.385 mg/mL protein equivalent and 
TRIS-HCL buffer was mixed with either ~4 µl of; acetylcodeine, acetyl salicylic 
acid, caffeine, cocaine, compound 3, compound 4 EtOH, lidocaine, loperamide 
or procaine with concentrations between 6.1-61 µM. This mixture (total volume 
of 0.2 ml) was pre-incubated at 37 ºC for 5 min. Further 4 µl of 6-AM solution 
(6.1 µM) was added and the incubation continued for 15 min at 37 ºC. The 
reaction was stopped by adding 200 µl ice-cold acetonitrile and placing the test 
tubes on ice. The internal standard, codeine-d3, was added (10 µl) together with 
10 µl of the sample solution and 80 µl 0.1 % aqueous formic acid in an 
autosampler vial prior analysis.  
3.4 BIOANALYSIS 
3.4.1 LC-MS/MS Study I-IV 
Quantification of opiates was performed with LC-MS/MS. The LC system 
consisted of an AQUITY UPLC system connected to a Quattro Premiere XE or a 
XEVO TQ mass spectrometer (Waters, Milford, MA, USA). The tandem mass 
spectrometer was operated in positive electrospray mode using selected reaction 
monitoring (SRM). The specific transitions monitored are presented in each 
paper. Separation was achieved with reversed phase chromatography using an 
AQUITY UPLC HSS T3 2.1×100 mm, 1.8 µm or an AQUITY UPLC BEH C18 
2.1×100 mm, 1.7 µm. The mobile phase A consisted of a 0.1 %; aqueous formic 
acid and mobile phase B; methanol or acetonitrile. Gradient elution was used 
  18 
with a flow rate of 0.2 ml/min or 0.35 ml/min. The analytical column was always 
kept at 60 ºC. Different chromatographic systems were developed to obtain 
optimal retention and separation for the analytes of interest.  
3.4.2 LC-HRMS 
The LC system consisted of a Dionex Ultima 3000 coupled to a Thermo 
Scientific Q Exactive mass spectrometer (Fremont, CA, USA) operating in 
positive mode, full scan ranged within 90-1,350 m/z and a 70 000 resolution 
power. Separation was achieved on an AQUITY UPLC HSS T3 2.1×100 mm, 
1.8 µm with mobile phase consisted of 2 mM ammonium formate and 0.2 % 
ammonia solution (25 %). Mobile phase B consisted of 100 % methanol with the 
same amount of ammonium formate and ammonia. The column was kept at 50 
ºC and the flow rate was 0.3 ml/min with a total run time of 18 min.  
3.4.3 CEDIA immunoassay for opiates 
 
The screening assay was applied on an Olympus AU 640 (Beckman Coulter, 
Indianapolis, IN, USA) using CEDIA opiate reagents (Thermo Fisher 
Scientific, Waltham, MA, USA). Cut off at 300 ng/ml and the measuring range 
from 0-2000 ng/ml, 5.4 % CV at 390 ng/ml (n=212) and 6.7 % CV at 190 
ng/ml (n=214).  
3.4.4 DRI Ethyl Glucuronide and Ethyl Alcohol 
The screening assay for Ethyl glucuronide (EtG) and Ethyl alcohol (EtOH) were 
performed on an Olympus AU 640 using DRI enzyme EtOH enzyme assay and 
DRI EtG immunoassay from Thermo Fisher Scientific. The cut off for EtG is 
500 ng/ml and 5 mM for EtOH. The measuring range for EtG is 0-2.0 µg/ml, 4.5 
% CV at 0.375 µg/ml (n=211) and 3.2 % CV at 0.625 µg/ml (n=209). The 
measuring range for EtOH is 0-20.83, 6.1 % CV (n=210) at 2.55 mM and 4.2 % 
CV (n=210) at 7.5 mM.  
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3.4.5 GC-MS for opiates 
 
The GC-MS system used was a Thermo Finnigan Voyager Toxlab system 
(Thermo Electron Co, Waltham, MA, USA). The mass spectrometer was 
operated in the electron ionization mode using selected ion monitoring (73). 
The column used was a J&W DB-1701(30 m x 0.25 mm x 0.25 film thickness) 
(Agilent Technologies Inc., St. Clara, CA, USA). The carrier gas used was He.  
The total run time was approximately 20 min. The sample preparation 
consisted of hydrolysis by hydrochloric acid, automated solid phase extraction 
using Bond Elut Certify LRC 130mg from Agilent Technologies and formation 
of silyl derivatives. The cut off was 150 ng/ml for total morphine and codeine. 
For 6-AM the cut off was 10 ng/ml. For analysis of 6-AM the hydrolysis step 
was omitted. The inter assay imprecision (11) was below 10 %.  
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4 RESULTS 
4.1 STUDY I 
Synthesis and bioanalytical evaluation of morphine-3-O-sulfate and 
morphine-6-O-sulfate in human urine and plasma using LC-MS/MS 
4.1.1 Synthesis of M3S and M6S 
A new synthetic route was developed for synthesis of M6S and M3S.  
When following earlier reported procedures the product of M6S was impure as 
was revealed by careful LC-MS analysis. The resulting product was 
contaminated with residues of morphine. This observation was made when 
studying the intermediate product 3-acetylmorphine (3-AM). The acetylation 
process by Welsh resulted in 3-AM containing both the side-product heroin as 
well as unreacted morphine (74). In addition the purified 3-AM was unstable 
leading to degradation within days during dark and cold storage (-20 ºC) in the 
dark. This resulted in a mixture containing 3-AM, heroin and morphine.  
Regarding M3S the problem was obtaining the intermediate 6-AM in pure form. 
Earlier published procedures had to be improved. This was done by using a 
protective silyl group at the 6-position.  
The value of using careful LC-MS analysis for product characterization was 
demonstrated in this work. For example, the characterization of the purity of the 
intermediate product morphine-3-acetat-6-sulfat became of importance due to 
resulting in a final M6S pure product. Several batches contained impurities of 
residual, heroin and 6-AM (Figure 5). 
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These findings led to new developed procedures for the synthesis of M3S and 
M6S as dihydrates. Resulting in a high product purity >99.5 for M6S with an 
overall yield of 41 %. For M3S the purity was >98 % and an overall yield of 39 
%. In order to ascertain the correct product identity single X-ray analysis was 
used.  
4.1.2 Method development and validation  
Different chromatographic systems were evaluated resulting in using an 
ACQUITY HSS T3 2.1×100 mm, 1.8 µM with mobile phase A containing  0.1 
% aqueous formic acid and mobile phase B consisting of methanol. The 
chromatography selected was based on separation between M3S and M6S and 
the separation compared to the other morphine metabolites; M3G, M6G and 
morphine itself. Only one SRM transition was usable for the morphine sulfates 
and they were the same. For that reason identification was established by 
monitoring the analytes also in negative mode. Morphine-d3 was chosen as the 
internal standard for both sulfates  
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Figure 5 A chromatogram during characterisation of the 
intermediate morphine-3-acetat-6-sulfat batch 1878 with LC-MS 
using selected ion monitoring. This batch also contained impurities 
of 6-AM and heroin.  
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The measuring range for plasma was 5-500 ng/ml for M3S and 4.5-454 ng/ml 
for M6S. In urine the measuring range was 50-5000 ng/ml for M3S and for M6S 
45.4-4544 ng/ml. The response was linear in the measuring ranges. In Figure 6 a 
chromatogram of a urine calibrator is shown. The intra-assay and total 
imprecision had CV:s less than11 % with accuracy between 98-111 % for both 
analytes in urine and plasma. The matrix effect was of significance for both M3S 
and M6S in plasma, showing an average suppression of the signal of 37 % for 
M6S and 48 % for M3S. In urine, the suppression of the signal was <15 % for 
both analytes.  
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Figure 6 A chromatogram of a urine calibrator containing 500 ng/ml M3S 
and 454 ng/ml M6S. 
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4.1.3 Application 
Nine plasma samples were obtained from patient receiving morphine and 8 of 
the samples contained 5.8-12.9 ng/ml of M3S. In the 18 urine samples, probably 
from heroin intake, all contained detectable M3S and 13 samples quantifiable 
concentrations between 69-1500 ng/ml. No urine or plasma sample contained 
detectable concentrations of M6S. The LOD for M6S was 4 ng/ml in urine and 
0.3 ng/ml in plasma. In Table 2 the results are summarized.  
 
 
Study 
 
M3S 
 
M6S 
 
n ng/ml n ng/ml 
Plasma samples (n=9) 8 6-13 0 - 
Urine samples (n=18) 18 70-1500 0 - 
 
 
 
 
 
 
 
  
Table 2 M3S and M6S concentrations for the investigated patient samples 
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4.2 STUDY II 
Direct and efficient liquid chromatographic tandem mass spectrometric 
method for opiates in urine drug testing –Importance of 6-acetylmorphine and 
reduction of analytes 
4.2.1 Method design and validation 
The method was designed according to our previous work (75) but modified 
using Waters UPLC system and a more modern mass spectrometer.   
The measuring range for morphine and codeine was 150-1 000 000 ng/ml for 
M3G 150-600 000 ng/ml, for codeine glucuronide (CG) 150-400 000 ng/ml, for 
M6G 150-50 000 ng/ml and for 6-AM 2-30 000 ng/ml. The CV values for total 
imprecision were less than 16 % and the accuracy was within 96-106 %. 
External quality controls from the proficiency program College of American 
Pathologists showed good agreement for total morphine, codeine and 6-AM with 
an accuracy within 87-110 %. The matrix effect was extensive for the first 
eluting compound M3G, displaying an average suppression of the signal of 78 % 
in the addition experiment. When investigating the matrix effect with an infusion 
experiment M3G will elute during the recovery of the signal (Figure 7). 
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Figure 7 Blue line displays a chromatogram of infusing M3G (9500 ng/ml) 
at 10 µl/min while injecting a blank urine sample monitoring the SRM 
transition m/z 462 to 286. Green line is a chromatogram of M3G eluting at 
1.4 min.  
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The identification was based on correct relative retention times and ion ratio for 
two SRM products. Figure 8 shows an example chromatogram obtained from a 
sample collected after a heroin intake.  
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Figure 8 A chromatogram after a heroin intake containing 14 ng/ml 6-AM, 
4590 ng/ml M3G, 965 ng/ml M6G, 340 ng/ml morphine, 225 ng/ml CG. 
Codeine was below cutoff. 
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The qualitative method comparison with the reference GC-MS method showed 
good agreement. A number of 199 urine sample which were found positive in 
CEDIA opiate screening were analyzed with the GC-MS method and the LC-
MS/MS method. Comparison for total morphine and codeine is shown in Figure 
9. For total morphine only two samples deviated and contained concentrations 
close to the cut off. For total codeine one single sample deviated which were a 
false positive sample. The deviating results were within the uncertainty of the 
measurement.  
 
 
 
 
 
 
 
 
 
 
Figure 9 Method comparison using GC-MS as a reference method (n=199) 
showed 2 false negative samples for total morphine and one false positive 
for total codeine.  
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4.2.2 Interpretation strategy 
After this method had been in routine use for 3 years an evaluation of data was 
performed. The evaluation was made by using our data pool containing 3155 
samples (Figure 10) plotted according to total morphine and total codeine 
content. Total morphine consists of M3G, M6G and morphine. Total codeine 
consists of codeine and CG. Four clusters are revealed in the plot. Two 
containing only total morphine or codeine and the other two contains different 
proportions of morphine and codeine.  
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Figure 10 Results from 3155 authentic urine samples. Red dots are samples 
containing 6-AM, Blue dots represent samples from the medical care and 
green samples are from workplaces all are 6-AM negative. Values below cut 
off are depicted as zero.  
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4.2.2.1 Heroin intake 
Expected analytes after a heroin intake is mainly morphine and its metabolites, 
but also 6-AM, codeine and CG. A safe criterion for a heroin intake is presence 
of the heroin metabolite 6-AM. A number of 365 samples contained 6-AM. Of 
these there were 95 samples (26 %) that contained total morphine <2500 ng/ml. 
A heroin intake can also be defined by a ratio of total morphine over codeine 
without presence of 6-AM. The samples containing 6-AM and quantifiable 
concentrations of total morphine and codeine were used as reference to calculate 
a 95 % prediction interval. The frequency diagram is displayed in Figure 11 of 
the ratio total morphine over codeine for the samples containing 6-AM. The 
prediction interval was calculated to be 4.4-28.4.  
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Figure 11 A frequency diagram for samples containing 6-AM and 
quantifiable concentrations of total morphine over codeine (n=262). The 
mean ratio is 11.5 and a 95 % prediction interval is calculated to be 4.4-28 
for total morphine >2500 ng/ml. 
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When applying the ratio interval and the 6-AM criterion we get a total number of 
444 samples.  An addition of 78 samples fulfils the ratio interval criterion 
(Figure 12).  
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Figure 12 Samples that fulfil the  heroin  criteria’s. Red dots are samples 
containing 6-AM and blue and green dots are samples which fulfils the total 
morphine/codeine ratio 4.4-28.   
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4.2.2.2 Poppy seed 
Low concentrations of morphine may originate from dietary intake of poppy 
seed due to this reason a lower limit must be set. In this study the lower limit was 
set to 2500 ng/ml for total morphine. Though a codeine intake may also lead to 
low concentrations of total morphine therefore samples with a ratio >2 for total 
morphine over codeine must be fulfilled. Thus a poppy seed intake in our study 
is defined as total morphine < 2500 ng/ml with a ratio >2 for total morphine over 
codeine.  
4.2.2.3 Codeine 
For setting a criterion for a codeine intake we used the samples from workplaces 
as a reference population to calculate a 95 % prediction interval (coloured green 
in Figure 10). The interval was calculated to be 0.009-2.58 for a codeine intake. 
Another criterion for a codeine intake was samples that only contained codeine. 
Consequently a codeine intake in our study is defined as ratio <2.58 for total 
morphine over codeine or samples that contain only codeine.  
4.2.2.4 Morphine 
Samples that contain only total morphine above 2500 ng/ml and no detectable 
codeine or 6-AM is interpreted as a possible morphine intake or possible heroin 
intake.  
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4.2.2.5 Proposed interpretation strategy  
We have proposed a possible interpretation strategy on the basis of statistical 
calculations. The interpretation strategy is outlined in Figure 13 and is 
categorizing all urine samples in our data pool.  
 
  
 
 
 
 
 
Interpretation strategy
1. Heroin intake (n=365, 11.7 %)
-samples containing 6-AM 
2. Possible intake of morphine, codeine or poppy seed (n=862, 27.3 %)
-total morphine <2500 ng/ml and total morphine/codeine >2
3. Possible heroin intake (n=78, 2.5 %)
-total morphine/codeine ratio interval 4.4-28.4 without 6-AM
4. Codeine intake (n=1600, 50.7 %)
- total morphine/codeine ratio interval
<2.58 for total codeine 
-samples containing codeine only
5. Heroin/morphine intake (n=213, 6.7 %)
- samples containing only morphine > 2500 ng/ml
6. Residue (n=37, 1.2 %)
Figure 13 Proposed interpretation strategy 
 
  32 
4.2.3 Reduction of analytes 
The possibility to reduce the number of analytes in routine testing was also 
evaluated. The main component for the total morphine was M3G and for total 
codeine it was CG. M3G was present in 99.9 % in all of the morphine containing 
samples (n=2674). The fraction of M3G of total morphine was 84% ±14 (SD). 
CG was present in 99.6 % of the codeine containing samples (n=2021), with 
94% ±14 (SD) of total codeine being CG. Figure 14a-b displays M3G and CG in 
relations to total morphine and codeine in graphics.  
 
 
 
 
 
Figure 14a M3G was present in 99.9 % in all of the morphine containing samples 
(n=2674). The fraction of M3G of total morphine was 84% ±14 (SD) 
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The limits used in the interpretation strategy given in Figure13 were adjusted. 
When this was applied for interpretation of the data set it gave a categorization 
agreement of 98.7 %.  
  
99.6 % of all codeine
CG is present in 
containing samples
No CG Free codeine
8* <LOQ 215-1500
Being CG
Being
free codeine
* In six out of 8 samples CG was detected
Figure 14b CG was present in 99.6 % in all of the codeine containing samples (n=2021). 
The fraction of CG of total codeine was 93% ±12 (SD) 
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4.3 STUDY III 
On the presence of morphine-3-sulfate and morphine-6-sulfate in human 
urine and plasma, and formation in liver cytosol  
4.3.1 Method development 
Pronounced ion suppression for the first eluting compounds M3G and M3S in 
previous  studies  lead  to  investigations  with  “straight  phase”  chromatography.  
Also a new filtration technique for removal of phospholipids from plasma was 
tested. Unfortunately the results were not satisfying because the matrix effects 
were not much reduced, see Table 4. The retention order of the analytes did 
change using straight phase chromatography (SP) (Figure 15). However, this led 
us to go back to the initial reversed phase chromatography (RP) method. This 
work was presented as a poster at the IATDMCT conference in Salt Lake City, 
2013.  
 
Table 3 Validation of the matrix effect by addition experiments comparing different sample 
preparation and chromatography systems.  
 
M3S M6S M M6G M3G 
 
SP RP SP RP SP RP SP RP SP RP 
PPT -17 -67 -16 -24 -92 7 377 -12 376 -79 
Ostro -38 -37 -52 -18 -90 9 185 1 239 -76 
Phree -29 -33 -50 -5 -88 25 389 7 185 -80 
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4.3.2 Formation of M3S and M6S In Vitro  
Both M3S and M6S were formed, in-vitro (Figure 16). Only a small portion of 
morphine was converted to sulphates 0.0041 % of M3S and 0.010 % of M6S. 
The formation of the sulfated morphine metabolites was seen in both adult and 
fetal liver cytosol. The formation rate of M3S was 0.17 nmol/mg protein per 
minute (n=8) and for M6S the formation rate was 0.43 nmol/mg protein per 
minute (n=6) in the adult liver cytosol using a substrate concentration of 100 
µM. As a control, incubation was also performed with PAPS and morphine but 
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Figure 15 A chromatogram using straight phase chromatography with an 
ACQUITY BEH amide column 2.1x10 mm, 1.7 µm. The mobile phases 
consisted of 5 mM ammonium formate adjusted with formic acid to pH 3 and 
acetonitrile at a flow rate of 0.6 ml/min. The total time of analysis was 3.5 
minutes.   
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without cytosol. No sulfated morphine metabolites were found.
 
 
 
4.3.3 Presence of M3S and M6S in-vivo  
M3S was reconfirmed as a morphine metabolite in both urine and plasma in the 
in-vivo studies, see Table 5. As expected M3S concentrations are higher in the 
urine samples than for the plasma samples. In plasma M3S concentrations were 
in the range of 8-9 ng/ml. The M3S/M3G ratio differs significantly between the 
cancer patients and the newborn patients. For the newborn patients the median 
ratio was 30 times higher than for the cancer patients.  
The identfication of M6S as a morphine metabolite in-vivo was not as 
convincing. Only one plasma sample and one urine sample for M6S were 
detected. One plasma sample from the newborns study contained 7 ng/ml M6S. 
In the urine sample from the drug testing population M6S was detected at a 
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Figure16 A Chromatogram obtained of a morphine incubation with adult liver 
cytosol containing 7.6 nM M3S and 20 nM M6S, substrate concentration of 100 
µM.     
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concentration of 9 ng/ml.  The identification M6S was not convincing at these 
low concentrations since the qualifier ion intensities were weak.  
 
 
Study 
 
M3S 
  
M3S/M3G 
 
 
n ng/ml median n % median 
Cancer patients plasma (n=13) 6 5-54 8 6 0.29-0.54 0.41 
Newborn patients plasma (n=62) 17 5-21 9 17 2.66-24.1 12.7 
Cancer patients urine (n=12) 9 53-2920 180 9 0.84-3.38 1.39 
Drug testing urine (n=196) 88 52-1780 100 88 0.10-2.44 0.2 
 
 
  
Tabel 4 A summary of M3S in the in-vivo studies. 
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4.4 STUDY IV 
Studies on the inhibition of heroin metabolism 
4.4.1 Characterization of atypical samples 
The number urine samples in the data set that contained 6-AM was 693. 
Defining atypical samples by 6-AM >2ng/ml and total morphine <1000 ng/ml 
resulted in 125 samples (18 %). If using a more strict criterion with 6-AM >10 
ng/ml and total morphine <300 ng/ml the number of atypical samples was 80 
(11.5 %). When plotting a frequency diagram of the ratio 6-AM/total morphine a 
bimodal distribution was revealed, see Figure 17. Atypical samples were then 
defined as 6-AM/total morphine ration >0.26 ending up with 78 atypical samples 
(11.2 %).   
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Figure 17 Frequency plot over the 693 positive heroin 
samples. The 78 atypical samples are displayed in yellow 
bars with a ratio >0.26. 
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4.4.2 Study of 6-AM deacetylation in-vitro 
The in-vitro system that tested the activity of human liver homogenates provided 
an 86 % mean conversion rate of 6-AM to morphine displaying a large inter 
variability for the ten individuals CV=52 % (n=30). The strongest inhibition 
effect was seen for compound 3, compound 4 and loperamide. The in-vitro 
inhibition of morphine in the presence of each substrate is shown in Figure 18. 
For  some  “substrate”  there  was  a  large  intervariability for the inhibition effect. A 
diagram is shown in Figure 19 displaying  the  inhibition  for  each  “individual” 
when caffeine is being present in the incubation system.  For the liver tissue 76 
we got an inhibitory effect of 68 % but for the liver tissue 52 we only got 2 % 
inhibition.  
 
 
ASA
Caffeine
Cocaine
Compound 3
Compound 4
EtOH
Lidocaine
Loperamide
Procaine
In
hi
bi
tio
n 
%
Figure 18 In-vitro inhibition of morphine from 6-AM during presence of 
substrate. The strongest inhibition effect was seen for compound 3 (median= 
83), compound 4 (median= 59) and loperamide (median= 59).  
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4.4.3 Search for inhibitors in authentic samples  
An investigation was made to find possible inhibitors in authentic samples using 
different sample sets. Eighty patient samples which contained a ratio 6-AM/total 
morphine <0.26 ng/ml were screened for EtG and EtOH. EtG was present in 40 
% of the samples and EtOH was present in 5 % of the samples. In the samples 
with a ratio 6-AM/total morphine >0.26 ng/ml (n=35) EtG was present in 34 % 
of the samples and EtOH was present in 14 % of the samples. In another set of 
samples consisting of 40 atypical (6-AM >2ng/ml and total morphine <1000 ng) 
and 40 normal samples (6-AM >2ng/ml and total morphine >1000 ng) screening 
was performed with LC-MS/MS for five possible inhibitors; salicylic acid, 
cocaine, lidocaine, loperamide, procaine and heroin. Very few samples were 
above cutoff >1 µM (salicylic acid >750 ng/ml). Only salicylic acid was more 
pronounced in the atypical group for six samples.  
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Figure 19 A diagram of the inhibitory effect of caffeine during the 
 in-vitro conversion of 6-AM to morphine in ten individual liver 
tissues.
  41 
When searching for compound 3 detectable concentrations (< 1 ng/ml) were 
found in almost every sample (n=44).  There was a slightly higher mean peak 
area in the atypical samples. Compound 4 was not detected in any of the 
samples. The metabolite from compound 3, ATM3 and the metabolite for 
compound 4 ATM4 co-eluted but the peak areas were higher in the atypical 
samples. 
Forty-four samples were investigated using a non-targeted metabolomic 
approach with LC-HRMS. The samples were selected by a more strict criterion, 
categorizing the atypical group with a ratio 6AM/total morphine > 0.26, n=19. In 
the normal group a total of 25 samples were selected based on a ratio 6AM/total 
morphine <0.26.  
The samples were processed with the Sieve software program. Most of the 
components  were  more  abundant  in  the  “normal”  group.  As  expected  a  
significantly higher abundance for morphine-3-glucuronide and morphine-6-
glucuronide  were  seen  in  the  ”normal”  group.  No  obvious  candidates  for  having  
enzyme inhibition effects were revealed from the data analysis. 
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5 DISCUSSION 
This was the first study using mass spectrometry to study the presence of the 
conjugated sulphate morphine metabolites M3S and M6S. It was demonstrated 
that both M3S and M6S can form when studied in-vitro, but in small amounts. 
The in-vivo studies resulted in convincing evidence of M3S as a morphine 
metabolite in both urine and plasma using the criteria of retention time and 
monitoring two SRM transitions. However, there was only weak evidence that 
M6S actually forms in-vivo since only two samples contained M6S. The 
identification was not as convincing due to weak abundance of the qualifier 
transition. In earlier reported studies from Yeh and co-workers when 
determining M3S and (M6S) there were uncertainties in the analytical technique 
used (27, 28) since the selectivity using TLC is rather low. However, the Yeh 
studies proposed a formation of 1-5 % for M3Srelative to M3G in urine. This is 
in good agreement with our results. Since only small amounts of the sulfates are 
present in urine and plasma compared with the glucuronides it may be concluded 
that they can be neglected in most respects. Maybe M3S shold be considered 
when doing validation concerning possible interference in analytical methods for 
determination of morphine.  
The LC-MS/MS method for urine drug testing using direct injection has been 
demonstrated to be accurate and reliable in routine use. A method comparison 
against GC-MS, which is the golden standard technique in urine drug testing, 
was established (ref GC-MS methods). We verified a good agreement between 
the techniques when using the GC-MS method as a reference method. The 
possibilities using LC-MS/MS in urine drug testing is to have the option to 
simplify the sample preparation omitting the hydrolysis and derivatization and in 
some cases extraction (53).  
When omitting sample preparation and only dilute the urine matrix effect may be 
more pronounced (46). Since our method displayed ion suppression for the 
earlier metabolites M3G and morphine one might consider additional retention 
of M3G.  
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The aim to further simplify the analytical method by decreasing the number of 
analytes resulted in outlining a possible interpretation strategy. During 
evaluation of the data set we could display that a safe and reliable criterion for a 
heroin intake is to use 6-AM as a biomarker. 6-AM seems to be detected for a 
longer time in urine (46). We could detect 6-AM in 82 % (n=443) of all cases 
that could be attributed to a heroin intake displaying 6-AM as a sensitive 
biomarker.  
We have demonstrated that there is a possibility to reduce the number of analytes 
to further simplify the method. When decreasing the number of analytes to the 
main metabolites of morphine and codeine, M3G and CG. There were only a 
small fraction of samples containing free morphine and codeine.  
When the first developed method for M3S and M6S displayed ion suppression 
experiments were performed regarding changing the chromatography. 
Investigations were performed using different HILIC columns to retain the more 
hydrophilic morphine metabolites. As expected the hydrophilic M3G got the 
strongest retention though M3S still displayed a short retention on the column. 
The ion suppression did not improve significantly and for some analytes we got 
ion enhancement instead. Altogether we chose to continue with the original 
reversed phase chromatography.  
We could confirm the finding in earlier reports (41-45) about the existence of the 
atypical metabolite pattern after a heroin intake in some individuals. Euler and 
co-workers suggested that the inhibition could be attributed to high 
concentrations of heroin and/or 6-AM resulting in inhibition of the UGT2B7 
enzyme capacity or the CES:s enzyme. Another suggestion is that a heroin intake 
has occurred immediately after sampling. The third proposal refers to 
xenobiotics administered together with heroin or some unknown heroin 
constituent which will cause the inhibition of 6-AM (41). Our in-vitro studies 
displayed an inhibition of the conversion of 6-AM to morphine. This supported 
our initial hypothesis that the inhibition of carboxyesterase is caused by a 
substance ingested together with heroin. Regarding heroin constituents the 
rearrangement product from thebaine compound 3 showed a large inhibitory 
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effect (85 %) but only small amounts were found in the urine samples. Our 
conclusion is that it is likely that several substances contribute to the atypical 
pattern of heroin metabolism.  
To summarize, in this thesis we have developed a new method for detection of 
morphine sulphate metabolites thus enabling the monitoring of these metabolites 
in human samples. In addition, a validated routine LC-MS/MS method for urine 
drug testing of opiates has been developed and that 6-AM is a good and 
sufficient biomarker for heroin.  
 
 
  45 
6 CONCLUSION 
The following main conclusions can be drawn 
x Reference material for M3S and M6S has successfully been developed 
and are now accessible. For the first time an analytical method for 
quantification of M3S and M6S in urine and plasma have been developed 
with mass spectrometry. The formation of M3S and M6S are small both 
in-vivo and in-vitro nevertheless  we have demonstrated that both M3S 
and M6S are morphine metabolites.  
 
x A validated routine LC-MS/MS method for urine drug testing of opiates 
has been evaluated. The evaluation displayed that the 6-AM biomarker is 
a good and dependable criterion for a heroin intake. We have also 
demonstrated that this method can be reduced regarding number of 
analytes.  
 
x We have reconfirmed and demonstrated the atypical pattern after a heroin 
intake. The phenomenon of 6-AM inhibition seems to depend on several 
causes.  
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